Literature DB >> 32134149

Frontline Science: Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls.

Eva Knuplez1,2, Rebecca Krier-Burris1, Yun Cao1, Gunther Marsche2, Jeremy O'Sullivan1, Bruce S Bochner1.   

Abstract

Eosinophils are important multifunctional granulocytes. When studying eosinophil function and its contribution to diseases, mouse models are often used. Mouse eosinophils selectively express sialic acid-binding immunoglobulin-like lectin (Siglec)-F. Its closest functional paralog on human eosinophils is Siglec-8. These Siglecs are being used to target eosinophils when exploring their mechanistic roles in disease and for potential therapeutic benefit. In order to facilitate preclinical studies of human Siglec-8, we developed transgenic mouse strains expressing human Siglec-8 only on the surface of eosinophils with or without endogenous Siglec-F and have begun characterizing various cellular functions in vitro and in vivo. Eosinophils from Siglec-8+ mice, with or without Siglec-F, responded to Siglec-8 antibody engagement in vitro by up-regulating surface CD11b, whereas Siglec-F antibody had no such effect. Engagement of Siglec-F or Siglec-8 with respective antibodies in vitro resulted in only modest increases in cell death. Administration of rat Siglec-F antibodies to mice led to a significant decrease in Siglec-F surface expression on eosinophils due to internalization, and thus appeared to decrease eosinophil numbers based on Siglec-F+ cells, but with proper gaiting strategies did not in fact result in significant eosinophil depletion. In marked contrast, administration of mouse Siglec-8 antibodies rapidly and effectively depleted eosinophils from blood and spleens of mice, but an F(ab')2 version did not, indicating an Fc-mediated mechanism for eosinophil depletion in vivo. Siglec-8 expressing mice with or without endogenous Siglec-F will be useful to study Siglec-8-based therapeutics, and may be a preferred approach when acute or chronic eosinophil depletion is needed. ©2020 Society for Leukocyte Biology.

Entities:  

Keywords:  Siglec-8; Siglec-F; antibody-dependent cellular cytotoxicity; depletion; eosinophils

Mesh:

Substances:

Year:  2020        PMID: 32134149      PMCID: PMC7585130          DOI: 10.1002/JLB.3HI0120-381R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  43 in total

1.  Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells.

Authors:  Ibrahim M Sektioglu; Rafael Carretero; Nadja Bulbuc; Tobias Bald; Thomas Tüting; Alexander Y Rudensky; Günter J Hämmerling
Journal:  Cancer Res       Date:  2016-11-22       Impact factor: 12.701

Review 2.  Human versus mouse eosinophils: "that which we call an eosinophil, by any other name would stain as red".

Authors:  James J Lee; Elizabeth A Jacobsen; Sergei I Ochkur; Michael P McGarry; Rachel M Condjella; Alfred D Doyle; Huijun Luo; Katie R Zellner; Cheryl A Protheroe; Lian Willetts; William E Lesuer; Dana C Colbert; Richard A Helmers; Paige Lacy; Redwan Moqbel; Nancy A Lee
Journal:  J Allergy Clin Immunol       Date:  2012-09       Impact factor: 10.793

3.  Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma.

Authors:  William W Busse; Rohit Katial; David Gossage; Suha Sari; Bing Wang; Roland Kolbeck; Anthony J Coyle; Masamichi Koike; George L Spitalny; Peter A Kiener; Gregory P Geba; Nestor A Molfino
Journal:  J Allergy Clin Immunol       Date:  2010-06       Impact factor: 10.793

4.  Defining a link with asthma in mice congenitally deficient in eosinophils.

Authors:  James J Lee; Dawn Dimina; MiMi P Macias; Sergei I Ochkur; Michael P McGarry; Katie R O'Neill; Cheryl Protheroe; Ralph Pero; Thanh Nguyen; Stephania A Cormier; Elizabeth Lenkiewicz; Dana Colbert; Lisa Rinaldi; Steven J Ackerman; Charles G Irvin; Nancy A Lee
Journal:  Science       Date:  2004-09-17       Impact factor: 47.728

5.  Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity.

Authors:  Hiroaki Tateno; Hongyi Li; Melissa J Schur; Nicolai Bovin; Paul R Crocker; Warren W Wakarchuk; James C Paulson
Journal:  Mol Cell Biol       Date:  2007-06-11       Impact factor: 4.272

6.  Eosinophils are not required for the induction and maintenance of an alloantibody response.

Authors:  P Cravedi; D A Lessman; P S Heeger
Journal:  Am J Transplant       Date:  2013-08-06       Impact factor: 8.086

7.  Frontline Science: Characterization of a novel mouse strain expressing human Siglec-8 only on eosinophils.

Authors:  Jeremy A O'Sullivan; Yadong Wei; Daniela J Carroll; Liliana Moreno-Vinasco; Yun Cao; Fengrui Zhang; James J Lee; Zhou Zhu; Bruce S Bochner
Journal:  J Leukoc Biol       Date:  2018-03-30       Impact factor: 4.962

8.  Eosinophil differentiation in the bone marrow is promoted by protein tyrosine phosphatase SHP2.

Authors:  L-x Xia; W Hua; Y Jin; B-p Tian; Z-w Qiu; C Zhang; L-q Che; H-b Zhou; Y-f Wu; H-q Huang; F Lan; Y-h Ke; J J Lee; W Li; S-m Ying; Z-h Chen; H-h Shen
Journal:  Cell Death Dis       Date:  2016-04-07       Impact factor: 8.469

9.  Siglec-F is a novel intestinal M cell marker.

Authors:  Nadezhda Gicheva; Matthew S Macauley; Britni M Arlian; James C Paulson; Norihito Kawasaki
Journal:  Biochem Biophys Res Commun       Date:  2016-08-11       Impact factor: 3.575

10.  Identification of a Siglec-F+ granulocyte-macrophage progenitor.

Authors:  Jessica E Bolden; Erin C Lucas; Geyu Zhou; Jeremy A O'Sullivan; Carolyn A de Graaf; Mark D McKenzie; Ladina Di Rago; Tracey M Baldwin; Jake Shortt; Warren S Alexander; Bruce S Bochner; Matthew E Ritchie; Douglas J Hilton; Kirsten A Fairfax
Journal:  J Leukoc Biol       Date:  2018-04-12       Impact factor: 4.962

View more
  8 in total

1.  Divergent Siglec-F(eights) of mouse and human eosinophil death.

Authors:  Elizabeth A Jacobsen
Journal:  J Leukoc Biol       Date:  2020-06-18       Impact factor: 4.962

2.  Siglec-F Promotes IL-33-Induced Cytokine Release from Bone Marrow-Derived Eosinophils Independently of the ITIM and ITIM-like Motif Phosphorylation.

Authors:  Stefanie Westermann; Axel Dietschmann; Daniela Doehler; Kirstin Castiglione; Bruce S Bochner; David Voehringer; Daniel Radtke
Journal:  J Immunol       Date:  2022-01-07       Impact factor: 5.426

3.  Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.

Authors:  Elizabeth A Jacobsen; David J Jackson; Enrico Heffler; Sameer K Mathur; Albert J Bredenoord; Ian D Pavord; Praveen Akuthota; Florence Roufosse; Marc E Rothenberg
Journal:  Annu Rev Immunol       Date:  2021-03-01       Impact factor: 28.527

4.  Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.

Authors:  Jason Gotlib; Tracy I George; Melody C Carter; K Frank Austen; Bruce Bochner; Daniel F Dwyer; Jonathan J Lyons; Matthew J Hamilton; Joseph Butterfield; Patrizia Bonadonna; Catherine Weiler; Stephen J Galli; Lawrence B Schwartz; Hanneke Oude Elberink; Anne Maitland; Theoharis Theoharides; Celalettin Ustun; Hans-Peter Horny; Alberto Orfao; Michael Deininger; Deepti Radia; Mohamad Jawhar; Hanneke Kluin-Nelemans; Dean D Metcalfe; Michel Arock; Wolfgang R Sperr; Peter Valent; Mariana Castells; Cem Akin
Journal:  J Allergy Clin Immunol       Date:  2021-03-11       Impact factor: 14.290

Review 5.  Discovery, Function, and Therapeutic Targeting of Siglec-8.

Authors:  Bradford A Youngblood; John Leung; Rustom Falahati; Jason Williams; Julia Schanin; Emily C Brock; Bhupinder Singh; Alan T Chang; Jeremy A O'Sullivan; Robert P Schleimer; Nenad Tomasevic; Christopher R Bebbington; Bruce S Bochner
Journal:  Cells       Date:  2020-12-24       Impact factor: 6.600

6.  IL-33 reduces tumor growth in models of colorectal cancer with the help of eosinophils.

Authors:  Melanie Kienzl; Carina Hasenoehrl; Paulina Valadez-Cosmes; Kathrin Maitz; Arailym Sarsembayeva; Eva Sturm; Akos Heinemann; Julia Kargl; Rudolf Schicho
Journal:  Oncoimmunology       Date:  2020-06-16       Impact factor: 8.110

7.  A FACS-based approach to obtain viable eosinophils from human adipose tissue.

Authors:  James D Hernandez; Ben Yi Tew; Ting Li; Gerald C Gooden; Hamza Ghannam; Mia Masuda; James Madura; Bodour Salhia; Elizabeth A Jacobsen; Eleanna De Filippis
Journal:  Sci Rep       Date:  2020-08-06       Impact factor: 4.379

8.  The anti-parasitic drug miltefosine suppresses activation of human eosinophils and ameliorates allergic inflammation in mice.

Authors:  Eva Knuplez; Melanie Kienzl; Athina Trakaki; Rudolf Schicho; Akos Heinemann; Eva M Sturm; Gunther Marsche
Journal:  Br J Pharmacol       Date:  2021-02-02       Impact factor: 9.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.